Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASF-1075 topical cream for prevention and treatment of nickel-induced contact dermatitis
2005-005792-15Phase 2Completed
- Sponsor
- Astion Pharma
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ASF-1075 in contact hypersensitivity (4 arms), sponsored by Astion Pharma. Primary endpoint: Cumulative clinical skin reaction score (days 3 to 7). Started Jan 2006; status: completed.
02
Drugs
ASF-1075
03
Conditions
contact hypersensitivity
Beyond the preview
Go deeper on 2005-005792-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005792-15.